Naturhouse Health (0R9G) Ratios
Naturhouse Health Ratios
GB:0R9G's free cash flow for Q2 2026 was $3.18M. For the 2026 fiscal year, GB:0R9G's free cash flow was decreased by $-28.50K and operating cash flow was $3.21M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.65 | 4.36 | 2.69 | 3.23 | 4.62 |
| Quick Ratio | 1.40 | 3.83 | 2.48 | 2.91 | 4.31 |
| Cash Ratio | 1.13 | 3.20 | 1.91 | 1.44 | 3.38 |
| Solvency Ratio | 0.72 | 1.08 | 0.74 | 0.80 | 1.22 |
| Operating Cash Flow Ratio | 1.02 | 1.79 | 1.64 | 0.85 | 2.01 |
| Short-Term Operating Cash Flow Coverage | 21.31 | 93.98 | 145.49 | 21.84 | 165.03 |
| Net Current Asset Value | $ 3.92M | $ 17.27M | $ 16.16M | $ 12.11M | $ 24.36M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.10 | 0.10 | 0.10 | 0.13 | 0.09 |
| Debt-to-Equity Ratio | 0.19 | 0.13 | 0.16 | 0.19 | 0.12 |
| Debt-to-Capital Ratio | 0.16 | 0.12 | 0.14 | 0.16 | 0.11 |
| Long-Term Debt-to-Capital Ratio | 0.05 | 0.03 | 0.05 | 0.06 | 0.05 |
| Financial Leverage Ratio | 1.88 | 1.34 | 1.59 | 1.54 | 1.36 |
| Debt Service Coverage Ratio | 16.48 | 45.62 | 54.85 | 22.83 | 80.42 |
| Interest Coverage Ratio | 151.25 | 94.60 | 152.00 | 62.39 | 173.38 |
| Debt to Market Cap | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 |
| Interest Debt Per Share | 0.06 | 0.07 | 0.09 | 0.09 | 0.07 |
| Net Debt to EBITDA | -0.69 | -1.05 | -1.08 | -0.43 | -1.10 |
| Profitability Margins | |||||
| Gross Profit Margin | 27.17% | 71.75% | 49.81% | 71.53% | 71.64% |
| EBIT Margin | 27.95% | 27.68% | 31.09% | 25.40% | 31.85% |
| EBITDA Margin | 30.33% | 31.63% | 35.58% | 29.78% | 36.12% |
| Operating Profit Margin | 27.95% | 26.60% | 32.27% | 24.53% | 30.10% |
| Pretax Profit Margin | 28.75% | 27.40% | 30.58% | 25.00% | 31.68% |
| Net Profit Margin | 21.19% | 19.96% | 22.40% | 18.37% | 23.20% |
| Continuous Operations Profit Margin | 21.19% | 19.96% | 22.31% | 18.36% | 23.21% |
| Net Income Per EBT | 73.71% | 72.83% | 73.26% | 73.47% | 73.23% |
| EBT Per EBIT | 102.89% | 102.99% | 94.78% | 101.95% | 105.23% |
| Return on Assets (ROA) | 30.19% | 23.16% | 23.12% | 22.48% | 27.27% |
| Return on Equity (ROE) | 56.86% | 31.13% | 36.87% | 34.62% | 37.09% |
| Return on Capital Employed (ROCE) | 61.75% | 36.39% | 45.07% | 37.34% | 42.35% |
| Return on Invested Capital (ROIC) | 44.34% | 25.79% | 31.56% | 26.25% | 30.29% |
| Return on Tangible Assets | 30.53% | 23.36% | 23.33% | 22.81% | 27.69% |
| Earnings Yield | 7.73% | 9.91% | 11.63% | 10.16% | 11.55% |
| Efficiency Ratios | |||||
| Receivables Turnover | 22.65 | 20.97 | 20.05 | 21.81 | 8.60 |
| Payables Turnover | 15.12 | 3.85 | 6.18 | 4.42 | 5.11 |
| Inventory Turnover | 11.89 | 4.05 | 9.19 | 5.59 | 6.50 |
| Fixed Asset Turnover | 18.37 | 14.83 | 13.75 | 13.17 | 21.54 |
| Asset Turnover | 1.42 | 1.16 | 1.03 | 1.22 | 1.18 |
| Working Capital Turnover Ratio | 3.24 | 2.28 | 2.50 | 2.19 | 2.18 |
| Cash Conversion Cycle | 22.67 | 12.65 | -1.12 | -0.56 | 27.11 |
| Days of Sales Outstanding | 16.12 | 17.41 | 18.20 | 16.74 | 42.44 |
| Days of Inventory Outstanding | 30.69 | 90.06 | 39.72 | 65.29 | 56.14 |
| Days of Payables Outstanding | 24.14 | 94.82 | 59.04 | 82.59 | 71.46 |
| Operating Cycle | 46.81 | 107.47 | 57.92 | 82.03 | 98.57 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.20 | 0.19 | 0.35 | 0.12 | 0.27 |
| Free Cash Flow Per Share | 0.20 | 0.19 | 0.34 | 0.10 | 0.27 |
| Dividend Paid and CapEx Coverage Ratio | 0.66 | 0.94 | 3.19 | 0.37 | 4.43 |
| Capital Expenditure Coverage Ratio | 25.73 | 34.20 | 36.75 | 7.36 | 323.46 |
| Operating Cash Flow Coverage Ratio | 3.54 | 2.71 | 4.15 | 1.32 | 3.70 |
| Operating Cash Flow to Sales Ratio | 0.26 | 0.23 | 0.42 | 0.14 | 0.28 |
| Free Cash Flow Yield | 8.94% | 11.28% | 20.98% | 6.47% | 13.93% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 12.94 | 10.38 | 8.60 | 9.84 | 8.66 |
| Price-to-Sales (P/S) Ratio | 2.74 | 2.01 | 1.93 | 1.81 | 2.01 |
| Price-to-Book (P/B) Ratio | 7.36 | 3.14 | 3.17 | 3.41 | 3.21 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 11.19 | 8.87 | 4.77 | 15.44 | 7.18 |
| Price-to-Operating Cash Flow Ratio | 10.75 | 8.61 | 4.64 | 13.35 | 7.15 |
| Price-to-Earnings Growth (PEG) Ratio | 2.07 | -0.66 | 0.46 | -0.36 | 0.23 |
| Enterprise Value Multiple | 8.35 | 5.32 | 4.34 | 5.64 | 4.46 |
| Enterprise Value | 120.63M | 83.11M | 77.78M | 87.99M | 92.82M |
| EV to EBITDA | 8.35 | 5.32 | 4.34 | 5.64 | 4.46 |
| EV to Sales | 2.53 | 1.68 | 1.54 | 1.68 | 1.61 |
| EV to Free Cash Flow | 10.33 | 7.41 | 3.82 | 14.35 | 5.76 |
| EV to Operating Cash Flow | 9.93 | 7.19 | 3.71 | 12.40 | 5.74 |
| Tangible Book Value Per Share | 0.29 | 0.52 | 0.50 | 0.45 | 0.59 |
| Shareholders’ Equity Per Share | 0.30 | 0.53 | 0.51 | 0.46 | 0.60 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.26 | 0.27 | 0.27 | 0.27 | 0.27 |
| Revenue Per Share | 0.80 | 0.82 | 0.84 | 0.87 | 0.96 |
| Net Income Per Share | 0.17 | 0.16 | 0.19 | 0.16 | 0.22 |
| Tax Burden | 0.74 | 0.73 | 0.73 | 0.73 | 0.73 |
| Interest Burden | 1.03 | 0.99 | 0.98 | 0.98 | 0.99 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.23 | 0.21 | 0.20 | 0.21 | 0.19 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.20 | 0.85 | 1.86 | 0.54 | 0.89 |
Currency in EUR
